Trials / Completed
CompletedNCT01272284
The Altis® Single Incision Sling System for Female Stress Urinary Incontinence Study
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 113 (actual)
- Sponsor
- Coloplast A/S · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
An international, multi-center, single arm, prospective clinical study designed to assess the safety and efficacy of the Coloplast Altis single incision sling system for females with stress urinary incontinence (SUI).
Detailed description
An international, multi-center, single arm, prospective clinical study designed to assess the safety and efficacy of the Coloplast Altis single incision sling system for females with stress urinary incontinence (SUI). Primary Objective: Improvement in continence measured by 24 hour pad weight test with at least a 50% reduction in weight from baseline at 6 months. Secondary Objectives: Cough stress test results at 6 months; Subject QoL as measured by validated questionnaires: PGI-I, improvements in UDI-6 and IIQ-7 scores from baseline at 6 months, 3 day voiding diary improvement from baseline at 6 months; Device and procedure related adverse events. Brief Entrance Criteria: Adult female with confirmed SUI through cough stress test or urodynamics; Failed two non-invasive incontinence therapies; No prior surgical SUI treatment; No prolapse POP-Q Stage 2 or higher; No concurrent pelvic floor procedure; No urge predominant incontinence; No incontinence due to neurological disorder/disease; No PVR \> 100cc; and, No contraindication to the surgical procedure. Study visits will take place at baseline, implant/hospitalization, 3 months, 6 months, 1 year, and 2 years post operatively. This study will enroll up to 113 subjects at up to 17 investigative sites in the US and Internationally.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Altis® Single Incision Sling System (SIS) | The Altis® SIS is a permanently implantable synthetic sling for females placed at the mid-urethra to provide a scaffold for tissue in-growth and support for stress urinary incontinence. |
Timeline
- Start date
- 2010-12-01
- Primary completion
- 2012-07-01
- Completion
- 2014-01-01
- First posted
- 2011-01-07
- Last updated
- 2021-02-11
- Results posted
- 2013-11-28
Locations
17 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT01272284. Inclusion in this directory is not an endorsement.